Pernix Therapeutics (PTX) Posts Q3 Loss of 2c/Share

Pernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($0.02), $0.02 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $31.5 million versus the consensus estimate of $28.1 million.

Pernix Therapeutics reaffirmed FY2014 guidance.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell